Table 1.
Characteristics of included studies
| Study | Year | Country | Age, years | Type | Criteria | FC, µg/g | Method | TP | FP | FN | TN |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Carlsen et al. [30] | 2018 | Multicenter | 44 (29–52) | Prospective | MES 0 | 25 | ELISA | 10 | 6 | 15 | 64 |
| Goll et al. [24] | 2019 | Norway | NA | Prospective | MES 0 | 28 | ELISA | 16 | 11 | 26 | 51 |
| Theede et al. [25] | 2016 | Denmark | 39.3 (13.92) | Prospective | HS 0 | 45 | ELISA | 28 | 0 | 33 | 8 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0 | 50 | ELISA | 29 | 77 | 4 | 84 |
| Patel et al. [16] | 2017 | USA | 26 (2–56) | Retrospective | PRO2 0 + MES 0 | 60 | ELISA | 12 | 2 | 2 | 52 |
| Kristensen et al. [22] | 2015 | Norway | 35.5 (18–72) | Prospective | MES 0 | 61 | ELISA | 37 | 3 | 7 | 15 |
| Kim et al. [20] | 2020 | Korea | 50 (18–81) | Prospective | MES 0 | 70 | ELISA | 58 | 18 | 7 | 44 |
| Carlsen et al. [30] | 2018 | Multicenter | 44 (29–52) | Prospective | MES 0 + Geboes 0/1 | 74 | ELISA | 11 | 26 | 1 | 51 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0 | 75 | ELISA | 28 | 53 | 5 | 108 |
| Kristensen et al. [22] | 2015 | Norway | 35.5 (18–72) | Prospective | MES 0 | 96 | ELISA | 40 | 3 | 4 | 15 |
| Kim et al. [20] | 2020 | Korea | 50 (18–81) | Prospective | MES 0 | 100 | ELISA | 58 | 21 | 7 | 41 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0 | 100 | ELISA | 27 | 53 | 6 | 108 |
| Goll et al. [24] | 2019 | Norway | NA | Prospective | MES 0 | 100 | ELISA | 36 | 25 | 6 | 37 |
| Lee et al. [19] | 2019 | Korea | 48.4±13.2 (23–80) | Prospective | MES 0 | 150 | QPOCT | 6 | 0 | 1 | 22 |
| Carlsen et al. [30] | 2018 | Multicenter | 44 (29–52) | Prospective | MES 0 + Geboes 0/1 | 150 | ELISA | 11 | 36 | 1 | 41 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0 | 150 | ELISA | 26 | 41 | 7 | 120 |
| Ryu et al. [17] | 2019 | Korea | 47.2 (16–78) | Retrospective | MES 0 | 170 | ELISA | 40 | 31 | 11 | 92 |
| Hiraoka et al. [11] | 2018 | Japan | 32 (22–43) | Prospective | MES 0 | 180 | ELISA | 84 | 24 | 38 | 75 |
| Theede et al. [15] | 2015 | Denmark | 19–79 | Retrospective | MES 0 | 192 | ELISA | 24 | 10 | 8 | 78 |
| Yamaguchi et al. [29] | 2016 | Multicenter | 45 (36–54) | Prospective | MES 0 | 194 | ELISA | 37 | 22 | 15 | 31 |
| Takashima et al. [8] | 2015 | Japan | 35.5 (14–77) | Prospective | MES 0 | 200 | ELISA | 34 | 17 | 10 | 44 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0 | 200 | ELISA | 23 | 29 | 10 | 132 |
| Mak et al. [26] | 2018 | USA | 36.0±18.7 | Prospective | MES 0 | 200 | ELISA | 4 | 11 | 1 | 45 |
| Lee et al. [19] | 2019 | Korea | 48.4±13.2 (23–80) | Prospective | MES 0 | 201 | ELISA | 5 | 0 | 2 | 22 |
| Ryu et al. [17] | 2019 | Korea | 47.2 (16–78) | Retrospective | UCEIS 0/1 | 170 | ELISA | 44 | 27 | 15 | 98 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0–1 | 200 | ELISA | 26 | 69 | 7 | 92 |
| Yamaguchi et al. [29] | 2016 | Multicenter | 45 (36–54) | Prospective | MES 0–1 | 200 | ELISA | 63 | 1 | 31 | 10 |
| Mak et al. [26] | 2018 | USA | 36.0±18.7 | Prospective | HS | 200 | ELISA | 5 | 13 | 2 | 41 |
| Takashima et al. [8] | 2015 | Japan | 35.5 (14–77) | Prospective | MES 0–1 | 250 | ELISA | 45 | 14 | 19 | 27 |
| Kristensen et al. [23] | 2017 | Norway | 31 (18–60) | Prospective | MES 0–1 | 250 | ELISA | 16 | 0 | 3 | 1 |
| Sandborn et al. [28] | 2016 | Multicenter | 39.9±15.1 | Prospective | MES 0–1 | 250 | ELISA | 25 | 68 | 8 | 93 |
| D'Haens et al. [21] | 2012 | Belgium | 38 (30–46) | Prospective | MES 0/1 | 250 | ELISA | 14 | 3 | 4 | 18 |
| Mak et al. [26] | 2018 | USA | 36.0±18.7 | Prospective | MES 0–1 | 250 | ELISA | 3 | 13 | 2 | 43 |
| Kristensen et al. [22] | 2015 | Norway | 35.5 (18–72) | Prospective | MES 0–1 | 259 | ELISA | 25 | 9 | 5 | 23 |
| Arai et al. [18] | 2017 | Japan | 31.8 (15–69) | Prospective | SES-CD 0 | 180 | ELISA | 4 | 1 | 6 | 13 |
| Inokuchi et al. [9] | 2016 | Japan | 32 (22–43) | Prospective | SES-CD 0 | 180 | ELISA | 20 | 14 | 3 | 34 |
| Ma et al. [10] | 2017 | Canada | 47.9 (22–75) | Prospective | SES-CD 0 | 215 | ELISA | 36 | 12 | 7 | 31 |
| Zubin and Peter [27] | 2015 | Australia | 13.5 (12.2–13.88) | Prospective | SES-CD 0 | 250 | ELISA | 11 | 4 | 15 | 10 |
QPOCT, quantitative point-of-care test; ELISA, enzyme-linked immunosorbent assay; PRO2, patient-reported outcome measures; HS, histologic inflammatory activity score.